Affordable Access

deepdyve-link
Publisher Website

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors
Type
Published Article
Journal
Science
Publisher
American Association for the Advancement of Science (AAAS)
Volume
328
Issue
5981
Pages
1031–1035
Identifiers
DOI: 10.1126/science.1183057
Source
Ruoslahti Lab
License
Unknown

Abstract

Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy. We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue. Importantly, this effect did not require the drugs to be chemically conjugated to the peptide. Systemic injection with iRGD improved the therapeutic index of drugs of various compositions, including a small molecule (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab). Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.

Report this publication

Statistics

Seen <100 times